Madeleine Johnson

The firm expects to establish a US-based development and manufacturing footprint for its multiplex PCR assay kits.

The firm submitted a low-cost RT-LAMP device and COVID test to the FDA for Emergency Use Authorization this week.

The endpoint method uses so-called endogenous barcodes and molecular beacons to multiplex dozens of targets in a single reaction.

With new focus, the firm expects to grow its compound annual growth rate from 5.2 percent to 9 percent over the next few years.

Molecular diagnostics revenue dropped 47 percent due to lower volumes and selling prices for COVID-19 PCR products.

The firm has developed a technology to sort cells based on 11 non-fluorescent parameters and process up to one million cells per minute.

In a briefing with the media the agency described the status of US wastewater surveillance efforts and future directions.

A team in South Korea has developed a method that can increase sensitivity when paired with surface-enhanced Raman spectroscopy.

Newly merged with a firm founded by BioFire Diagnostics alums, Co-Diagnostics plans to develop small panels for the system with up to six targets.

The FDA thus far has not been interested in PCR tests to identify specific SARS-CoV-2 variants, but that may be changing with the emergence of Omicron.